Interplay of chronic obstructive pulmonary disease and colorectal cancer development: unravelling the mediating role of fatty acids through a comprehensive multi-omics analysis.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) patients often exhibit gastrointestinal symptoms, A potential association between COPD and Colorectal Cancer (CRC) has been indicated, warranting further examination. METHODS: In this study, we collected COPD and CRC data from the National Health and Nutrition Examination Survey, genome-wide association studies, and RNA sequence for a comprehensive analysis. We used weighted logistic regression to explore the association between COPD and CRC incidence risk. Mendelian randomization analysis was performed to assess the causal relationship between COPD and CRC, and cross-phenotype meta-analysis was conducted to pinpoint crucial loci. Multivariable mendelian randomization was used to uncover mediating factors connecting the two diseases. Our results were validated using both NHANES and GEO databases. RESULTS: In our analysis of the NHANES dataset, we identified COPD as a significant contributing factor to CRC development. MR analysis revealed that COPD increased the risk of CRC onset and progression (OR: 1.16, 95% CI 1.01-1.36). Cross-phenotype meta-analysis identified four critical genes associated with both CRC and COPD. Multivariable Mendelian randomization suggested body fat percentage, omega-3, omega-6, and the omega-3 to omega-6 ratio as potential mediating factors for both diseases, a finding consistent with the NHANES dataset. Further, the interrelation between fatty acid-related modules in COPD and CRC was demonstrated via weighted gene co-expression network analysis and Kyoto Encyclopedia of Genes and Genomes enrichment results using RNA expression data. CONCLUSIONS: This study provides novel insights into the interplay between COPD and CRC, highlighting the potential impact of COPD on the development of CRC. The identification of shared genes and mediating factors related to fatty acid metabolism deepens our understanding of the underlying mechanisms connecting these two diseases.

Introduce Ce3+ Ions to Realize Enhancement of C+L Band Luminescence of KMnF3: Yb, Er Nanoparticles.

Polymer-based waveguide amplifiers are essential components in integrated optical systems, as their gain bandwidths directly determine the operating wavelength of optical circuits. However, development of the wideband gain media has been challenging, making it difficult to fabricate devices with broadband amplification capability. Rare earth ion-doped nanoparticles (NPs) are a key component in the gain media, and their full width at half maximum (FWHM) of the emission peak decides the final gain bandwidth of the gain media. Here, KMnF3: Yb, Er, Ce@KMnF3: Yb NPs with the broad full width at half maximum (FWHM) of the emission peak covering the S+C band was prepared. The NPs were synthesized using a hydrothermal method, and the FWHM of the emission peak of NPs reached 76 nm under the excitation of a 980 nm laser. The introduction of Ce3+ ions and a core-shell structure coating greatly enhanced the emission intensity of NPs at C band. Since KMnF3: Yb, Er, Ce@KMnF3: Yb NPs have exceptional broadband luminescence properties at C band, KMnF3: Yb, Er, Ce@KMnF3: Yb NPs can be the potential gain medium in the future polymer-based waveguide amplifiers.

Gain enhancement technique for S-band polymer-based waveguide amplifiers.

The S-band polymer-based waveguide amplifier has been fabricated, but how to improve the gain performance remains a big challenge. Here, using the technique of establishing the energy transfer between different ions, we successfully improved the efficiency of Tm3+:3F3→3H4 and 3H5→3F4 transitions, resulting in the emission enhancement at 1480 nm and gain improvement in S-band. By doping the NaYF4:Tm,Yb,Ce@NaYF4 nanoparticles into the core layer, the polymer-based waveguide amplifier provided a maximum gain of 12.7 dB at 1480 nm, which was 6 dB higher than previous work. Our results indicated that the gain enhancement technique significantly improved the S-band gain performance and provided guidance for even other communication bands.

(S + C)-band polymer waveguide amplifier based on Tm3+ and Er3+ layer-doped core-shell nanoparticles.

Optical waveguide amplifiers are essential devices in integrated optical systems. Their gain bandwidths directly determine the operating wavelength of optical circuits. Due to the difficulty of developing wideband gain media, it has been a challenge to fabricate devices with broadband amplification capability, resulting in few reports on multi-band polymer waveguide amplifiers. Here, a polymer waveguide amplifier is demonstrated, which achieves loss compensation covering the whole (S + C) band by using NaYF4:Tm,Yb@NaYF4@NaYF4:Er nanoparticles (NPs)-doped SU-8 as the gain medium. The NPs with a layer-doped core-multishell structure not only provided two emitters required for (S + C)-band amplification, but also reduced the energy transfer (ET) between them. Under 980-nm excitation, the full width at half maximum (FWHM) of the emission peak of NPs reached 119 nm, and the relative gain in the (S + C) band was about 6-8 dB, successfully expanding the operating wavelength from single-band to multi-band.

Polymer-based S-band waveguide amplifier using NaYF4:Yb,Tm-PMMA nanocomposite as gain medium.

Optical waveguide amplifiers are essential to improve the performance of integrated communication systems. Previous research has mainly focused on C- and L-bands amplification, but there are few reports on S-band waveguide amplifiers. Here, we introduce a polymer-based waveguide amplifier that uses a NaYF4:Yb3+,Tm3+ nanoparticles-PMMA nanocomposite as gain medium, which can provide loss compensation in the S-band. To obtain the strongest emission luminescence at 1480 nm, we optimized the doping concentration of Yb3+ and Tm3+ to 20% and 1%, respectively. By copolymerizing the nanoparticles and methyl methacrylate monomers, the nanocomposite was synthesized and used as the gain medium to fabricate S-band waveguide amplifiers. A relative gain of 5.6 dB/cm was observed at 1480 nm under the excitation of a 980-nm pump laser. To the best of our knowledge, this is the first time that S-band amplification has been observed in a polymer-based waveguide amplifier. This result is expected to extend the waveband of polymer-based waveguide amplifiers to the S-band.

Polymer/silica hybrid waveguide amplifier at 532 nm based on NaYF4:Er3+, Yb3+ nanocrystals.

An optical waveguide amplifier, which can solve the problem of optical attenuation in optical network transmission, is the key technology to solve optical chip integration and optical interconnection. Here, to the best of our knowledge, we propose a novel polymer/silica hybrid waveguide amplifier at 532 nm for the first time. The research is of great significance to the improvement of short distance communication and visible light communication system. The waveguide amplifier was designed as an embedded structure based on NaYF4:Er3+Yb3+ nanocrystals, which were synthesized by high-temperature thermal decomposition. When the input signal power was 0.1 mW, and the pump power was 300 mW, a relative gain of 4.3 dB was obtained on an 8 mm waveguide. This result is of great research significance to break the distance limit and make all-optical transmission a reality.

A novel robust nomogram based on peripheral monocyte counts for predicting lymph node metastasis of prostate cancer.

Accurate methods for identifying pelvic lymph node metastasis (LNM) of prostate cancer (PCa) prior to surgery are still lacking. We aimed to investigate the predictive value of peripheral monocyte count (PMC) for LNM of PCa in this study. Two hundred and ninety-eight patients from three centers were divided into a training set (n = 125) and a validation set (n = 173). In the training set, the independent predictors of LNM were analyzed using univariate and multivariate logistic regression analyses, and the optimal cutoff value was calculated by the receiver operating characteristic (ROC) curve. The sensitivity and specificity of the optimal cutoff were authenticated in the validation cohort. Finally, a nomogram based on the PMC was constructed for predicting LNM. Multivariate analyses of the training cohort demonstrated that clinical T stage, preoperative Gleason score, and PMC were independent risk factors for LNM. The subsequent ROC analysis showed that the optimal cutoff value of PMC for diagnosing LNM was 0.405 × 109 l-1 with a sensitivity of 60.0% and a specificity of 67.8%. In the validation set, the optimal cutoff value showed significantly higher sensitivity than that of conventional magnetic resonance imaging (MRI) (0.619 vs 0.238, P < 0.001). The nomogram involving PMC, free prostate-specific antigen (fPSA), clinical T stage, preoperative Gleason score, and monocyte-to-lymphocyte ratio (MLR) was generated, which showed a robust predictive capacity for predicting LNM before the operation. Our results indicated that PMC as a single agent, or combined with other clinical parameters, showed a robust predictive capacity for LNM in PCa. It can be employed as a complementary factor for the decision of whether to conduct pelvic lymph node dissection.